Taken together, the data presented here support the notion that RAD51B loss-of-function germline variants result in increased breast and ovarian cancer predisposition and that biallelic loss of RAD51B in tumor cells leads to an HRD phenotype and potential sensitivity to HRD-targeting therapies. Here, RAD51B is linked to neoplasm.